KIORA PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
KPRX$1.51+4.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
ANNUAL REPORT ON FORM 10-K
For the Year Ended December 31, 2023
TABLE OF CONTENTS
| Page | ||
|---|---|---|
| Forward-Looking Statements | 2 | |
| PART I | ||
| Item 1. | Business | 3 |
| Item 1A. | Risk Factors | 18 |
| Item 1B. | Unresolved Staff Comments | 46 |
| Item 1C. | Cybersecurity | 46 |
| Item 2. | Properties | 48 |
| Item 3. | Legal Proceedings | 48 |
| Item 4. | Mine Safety Disclosures | 48 |
| PART II | ||
| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 49 |
| Item 6. | Reserved | 49 |
| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 49 |
| Item 7A. | Quantitative and Qualitative Disclosures About Market Risk | 58 |
| Item 8. | Consolidated Financial Statements and Supplementary Data | 58 |
| Item 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 58 |
| Item 9A. | Controls and Procedures | 59 |
| Item 9B. | Other Information | 60 |
| Item 9C. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 61 |
| PART III | ||
| Item 10. | Directors, Executive Officers and Corporate Governance | 62 |
| Item 11. | Executive Compensation | 62 |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 62 |
| Item 13. | Certain Relationships and Related Transactions, and Director Independence | 62 |
| Item 14. | Principal Accounting Fees and Services | 62 |
| PART IV | ||
| Item 15. | Exhibits, Consolidated Financial Statement Schedules | 63 |
| Index to Consolidated Financial Statements | F-1 | |
| Signatures | 92 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.